Cargando…

Improvement of Gram-negative Susceptibility to Fluoroquinolones After Implementation of a Pre-Authorization Policy for Fluoroquinolone Use: A Decade-Long Experience

BACKGROUND: Antibiotic use is a well-known risk factor for acquisition of drug-resistant bacteria and community antibiotic prescribing can drive high rates of resistance within the hospital setting. Owing to concerns over increasing fluoroquinolone (FQ) resistance among Gram-negative organisms at UA...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Rachael A, Scully, Morgan, Kunz, Danielle F, Jones, T Aaron, Camins, Bernard, McCarty, Todd P, Moser, Stephen, Hoesley, Craig J, Pappas, Peter G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632190/
http://dx.doi.org/10.1093/ofid/ofx162.048
_version_ 1783269650463719424
author Lee, Rachael A
Scully, Morgan
Kunz, Danielle F
Jones, T Aaron
Camins, Bernard
McCarty, Todd P
Moser, Stephen
Hoesley, Craig J
Pappas, Peter G
author_facet Lee, Rachael A
Scully, Morgan
Kunz, Danielle F
Jones, T Aaron
Camins, Bernard
McCarty, Todd P
Moser, Stephen
Hoesley, Craig J
Pappas, Peter G
author_sort Lee, Rachael A
collection PubMed
description BACKGROUND: Antibiotic use is a well-known risk factor for acquisition of drug-resistant bacteria and community antibiotic prescribing can drive high rates of resistance within the hospital setting. Owing to concerns over increasing fluoroquinolone (FQ) resistance among Gram-negative organisms at UAB Hospital, our stewardship program implemented a pre-authorization policy. The goal of this study was to assess the relationship between hospital fluoroquinolone use and antibiotic resistance. METHODS: In 2006, the inpatient formulary was consolidated to only ciprofloxacin and moxifloxacin with implementation of guidelines for use to limit inpatient prescribing. Any use outside of these guidelines required approval from an infectious diseases physician. Organism-specific data were obtained from the clinical microbiology database and FQ use was obtained from the hospital database. Correlations were calculated using Pearson’s coefficient. RESULTS: From 1998 to 2004, FQ use peaked at 173 days of therapy (DOT)/1,000 patient-days, but has remained below 60 DOT/1,000 patient-days since restriction implementation (Figure 1). FQ susceptibility was documented for five common Gram-negative isolates, P. aeruginosa, Acinetobacter spp., Enterobacter cloacae, E. coli, and K. pneumoniae, over an 18-year period (1998–2016). Common hospital acquired pathogens, including Pseudomonas aeruginosa, Acinetobacter spp. and Enterobacter cloacae improved in their susceptibilities to fluoroquinolones. Acinetobacter went from 35% to over 50% susceptible in the preceding 10 years after the policy. Pseudomonas improved from 50% susceptible to over 70% and Enterobacter improved from less than 50% to over 90% susceptible. Interestingly this improvement was not seen for E. coli which continued to show a decline in susceptibility from over 90% to near 60% in 2016. CONCLUSION: In a large academic hospital setting, FQ susceptibility for common hospital-acquired GNRS improved significantly with the introduction of a restricted use program. A continued decline in E. coli FQ susceptibility suggests resistance rates may be driven by outpatient and community antibiotic use and thus, outpatient stewardship programs are necessary to prevent further spread of FQ resistance. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-5632190
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56321902017-10-12 Improvement of Gram-negative Susceptibility to Fluoroquinolones After Implementation of a Pre-Authorization Policy for Fluoroquinolone Use: A Decade-Long Experience Lee, Rachael A Scully, Morgan Kunz, Danielle F Jones, T Aaron Camins, Bernard McCarty, Todd P Moser, Stephen Hoesley, Craig J Pappas, Peter G Open Forum Infect Dis Abstracts BACKGROUND: Antibiotic use is a well-known risk factor for acquisition of drug-resistant bacteria and community antibiotic prescribing can drive high rates of resistance within the hospital setting. Owing to concerns over increasing fluoroquinolone (FQ) resistance among Gram-negative organisms at UAB Hospital, our stewardship program implemented a pre-authorization policy. The goal of this study was to assess the relationship between hospital fluoroquinolone use and antibiotic resistance. METHODS: In 2006, the inpatient formulary was consolidated to only ciprofloxacin and moxifloxacin with implementation of guidelines for use to limit inpatient prescribing. Any use outside of these guidelines required approval from an infectious diseases physician. Organism-specific data were obtained from the clinical microbiology database and FQ use was obtained from the hospital database. Correlations were calculated using Pearson’s coefficient. RESULTS: From 1998 to 2004, FQ use peaked at 173 days of therapy (DOT)/1,000 patient-days, but has remained below 60 DOT/1,000 patient-days since restriction implementation (Figure 1). FQ susceptibility was documented for five common Gram-negative isolates, P. aeruginosa, Acinetobacter spp., Enterobacter cloacae, E. coli, and K. pneumoniae, over an 18-year period (1998–2016). Common hospital acquired pathogens, including Pseudomonas aeruginosa, Acinetobacter spp. and Enterobacter cloacae improved in their susceptibilities to fluoroquinolones. Acinetobacter went from 35% to over 50% susceptible in the preceding 10 years after the policy. Pseudomonas improved from 50% susceptible to over 70% and Enterobacter improved from less than 50% to over 90% susceptible. Interestingly this improvement was not seen for E. coli which continued to show a decline in susceptibility from over 90% to near 60% in 2016. CONCLUSION: In a large academic hospital setting, FQ susceptibility for common hospital-acquired GNRS improved significantly with the introduction of a restricted use program. A continued decline in E. coli FQ susceptibility suggests resistance rates may be driven by outpatient and community antibiotic use and thus, outpatient stewardship programs are necessary to prevent further spread of FQ resistance. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2017-10-04 /pmc/articles/PMC5632190/ http://dx.doi.org/10.1093/ofid/ofx162.048 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Lee, Rachael A
Scully, Morgan
Kunz, Danielle F
Jones, T Aaron
Camins, Bernard
McCarty, Todd P
Moser, Stephen
Hoesley, Craig J
Pappas, Peter G
Improvement of Gram-negative Susceptibility to Fluoroquinolones After Implementation of a Pre-Authorization Policy for Fluoroquinolone Use: A Decade-Long Experience
title Improvement of Gram-negative Susceptibility to Fluoroquinolones After Implementation of a Pre-Authorization Policy for Fluoroquinolone Use: A Decade-Long Experience
title_full Improvement of Gram-negative Susceptibility to Fluoroquinolones After Implementation of a Pre-Authorization Policy for Fluoroquinolone Use: A Decade-Long Experience
title_fullStr Improvement of Gram-negative Susceptibility to Fluoroquinolones After Implementation of a Pre-Authorization Policy for Fluoroquinolone Use: A Decade-Long Experience
title_full_unstemmed Improvement of Gram-negative Susceptibility to Fluoroquinolones After Implementation of a Pre-Authorization Policy for Fluoroquinolone Use: A Decade-Long Experience
title_short Improvement of Gram-negative Susceptibility to Fluoroquinolones After Implementation of a Pre-Authorization Policy for Fluoroquinolone Use: A Decade-Long Experience
title_sort improvement of gram-negative susceptibility to fluoroquinolones after implementation of a pre-authorization policy for fluoroquinolone use: a decade-long experience
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632190/
http://dx.doi.org/10.1093/ofid/ofx162.048
work_keys_str_mv AT leerachaela improvementofgramnegativesusceptibilitytofluoroquinolonesafterimplementationofapreauthorizationpolicyforfluoroquinoloneuseadecadelongexperience
AT scullymorgan improvementofgramnegativesusceptibilitytofluoroquinolonesafterimplementationofapreauthorizationpolicyforfluoroquinoloneuseadecadelongexperience
AT kunzdaniellef improvementofgramnegativesusceptibilitytofluoroquinolonesafterimplementationofapreauthorizationpolicyforfluoroquinoloneuseadecadelongexperience
AT jonestaaron improvementofgramnegativesusceptibilitytofluoroquinolonesafterimplementationofapreauthorizationpolicyforfluoroquinoloneuseadecadelongexperience
AT caminsbernard improvementofgramnegativesusceptibilitytofluoroquinolonesafterimplementationofapreauthorizationpolicyforfluoroquinoloneuseadecadelongexperience
AT mccartytoddp improvementofgramnegativesusceptibilitytofluoroquinolonesafterimplementationofapreauthorizationpolicyforfluoroquinoloneuseadecadelongexperience
AT moserstephen improvementofgramnegativesusceptibilitytofluoroquinolonesafterimplementationofapreauthorizationpolicyforfluoroquinoloneuseadecadelongexperience
AT hoesleycraigj improvementofgramnegativesusceptibilitytofluoroquinolonesafterimplementationofapreauthorizationpolicyforfluoroquinoloneuseadecadelongexperience
AT pappaspeterg improvementofgramnegativesusceptibilitytofluoroquinolonesafterimplementationofapreauthorizationpolicyforfluoroquinoloneuseadecadelongexperience